Market Cap 5.36B
Revenue (ttm) 329.00M
Net Income (ttm) 23.38M
EPS (ttm) N/A
PE Ratio 91.05
Forward PE 44.82
Profit Margin 7.11%
Debt to Equity Ratio 0.89
Volume 1,526,000
Avg Vol 1,852,118
Day's Range N/A - N/A
Shares Out 158.67M
Stochastic %K 45%
Beta 1.97
Analysts Strong Sell
Price Target $43.57

Company Profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's de...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 554 4484
Fax: 212 554 4531
Address:
3020 Carrington Mill Blvd., Suite 475, Morrisville, United States
jonyoyo
jonyoyo Oct. 31 at 7:31 AM
0 · Reply
nsilv
nsilv Oct. 31 at 4:54 AM
$TGTX Q3 earnings report will be a pivotal and consequential event. Q2-Q3, 2023 rev increase was $9M. Q2-Q3, 2024 rev increase was almost $11M. An $11M rev increase Q2-Q3, 2025 would place us at the current analysts' consensus estimate per Stocktwits, on pace with an easy lift to the full-year rev guidance of $570M-$575M. I'm thinking that, somewhere along the way, we're due for one of those $20M-$25M qoq rev increases that have popped up occasionally during B's growth phase. On the other hand, given the modest guidance set by MW, a Q3 revenue miss would likely have unpleasant consequences. Not make or break, but an important moment in B's growth story.
0 · Reply
1Timothy617
1Timothy617 Oct. 31 at 1:18 AM
$TGTX Usual playbook by MW - either tomorrow AH or Sunday /Monday night prob will be Mon/Tuesday AM
1 · Reply
spirit1
spirit1 Oct. 31 at 12:27 AM
$TGTX “SC Briumvi isn’t just a formulation—it’s a patients dream strategy. No infusion centers scheduling or driving to, lower co-pays over IV, and better adherence. Providers see no infusion center costs. TG’s Phase 3 SC enrollment is the quiet revolution. Kesimpta proved the model. TG will perfect it.” Truely a crown jewel in the making.
3 · Reply
InvestingIsFun45
InvestingIsFun45 Oct. 31 at 12:00 AM
$TGTX earnings slated for Nov 4. This is from Apple.
0 · Reply
BuyNowUnlimited
BuyNowUnlimited Oct. 30 at 11:36 PM
$TGTX i think they announce earnings date tomorrow
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 30 at 11:35 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $TGTX Current Share Price: $34.31 Contracts: $TGTX January 15, 2027 $35 Calls Scale in: $9.90- $12.10 Scale out: $15.40-$19.80 Can Easily Capture: 60% ROI Blended DTE: 442 Days | Join Elites here: https://liquidtheta.com
0 · Reply
investor757
investor757 Oct. 30 at 9:58 PM
$TGTX Today was my wife’s first Briumvi infusion. The first hour, they gave her a steroid, Benadryl and Tylenol. That next four hours was the actual infusion. I am happy to report that she did great. She had said that it was simple. Good to hear. That final next hour was just monitoring. She has had no side effects at all, and said the whole process was long, but a piece of cake. She was told that the side effects can happen up to the first 24 hours, but the nurse said that with all of the meds she’s been on in the past, they do not feel she may experience anything negative. She feels great right now, and I’m hoping that continues. Second dose is two weeks from today. I appreciate all of your positivity and kind word from my last post about the upcoming treatment. Though I strongly believe in this medication, you never know how someone will react. While I’m (we all are here) also here to make a lot of money off of this, to see the positive that it does for people is incredible.
ern1in
ern1in Oct. 30 at 9:14 PM
$TGTX Mike Weiss .... On a mission !
0 · Reply
ern1in
ern1in Oct. 30 at 9:09 PM
$TGTX 5:08 pm ..... BRIUMVI commercial !
0 · Reply
Latest News on TGTX
TG Therapeutics, Inc. (TGTX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 10:19 AM EDT - 3 months ago

TG Therapeutics, Inc. (TGTX) Q2 2025 Earnings Call Transcript


TG Therapeutics: Estimates Could Soon Be Raised Again

May 28, 2025, 6:00 AM EDT - 5 months ago

TG Therapeutics: Estimates Could Soon Be Raised Again


TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript

May 5, 2025, 10:55 AM EDT - 6 months ago

TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript


Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher

Mar 21, 2025, 11:50 AM EDT - 7 months ago

Stock Of The Day: TG Therapeutics Breaks Out, May Head Higher


TG Therapeutics: A Wonderful Hold

Mar 3, 2025, 3:59 PM EST - 8 months ago

TG Therapeutics: A Wonderful Hold


TG Therapeutics, Inc. (TGTX) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 11:55 AM EST - 8 months ago

TG Therapeutics, Inc. (TGTX) Q4 2024 Earnings Call Transcript


TG Therapeutics: 2025 Revenues Will Smash Expectations

Jan 21, 2025, 2:17 AM EST - 10 months ago

TG Therapeutics: 2025 Revenues Will Smash Expectations


TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst

Jan 13, 2025, 11:38 PM EST - 10 months ago

TG Therapeutics: Subcutaneous Briumvi Data A Key Near-Term Catalyst


TG Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 11:16 AM EST - 1 year ago

TG Therapeutics, Inc. (TGTX) Q3 2024 Earnings Call Transcript


jonyoyo
jonyoyo Oct. 31 at 7:31 AM
0 · Reply
nsilv
nsilv Oct. 31 at 4:54 AM
$TGTX Q3 earnings report will be a pivotal and consequential event. Q2-Q3, 2023 rev increase was $9M. Q2-Q3, 2024 rev increase was almost $11M. An $11M rev increase Q2-Q3, 2025 would place us at the current analysts' consensus estimate per Stocktwits, on pace with an easy lift to the full-year rev guidance of $570M-$575M. I'm thinking that, somewhere along the way, we're due for one of those $20M-$25M qoq rev increases that have popped up occasionally during B's growth phase. On the other hand, given the modest guidance set by MW, a Q3 revenue miss would likely have unpleasant consequences. Not make or break, but an important moment in B's growth story.
0 · Reply
1Timothy617
1Timothy617 Oct. 31 at 1:18 AM
$TGTX Usual playbook by MW - either tomorrow AH or Sunday /Monday night prob will be Mon/Tuesday AM
1 · Reply
spirit1
spirit1 Oct. 31 at 12:27 AM
$TGTX “SC Briumvi isn’t just a formulation—it’s a patients dream strategy. No infusion centers scheduling or driving to, lower co-pays over IV, and better adherence. Providers see no infusion center costs. TG’s Phase 3 SC enrollment is the quiet revolution. Kesimpta proved the model. TG will perfect it.” Truely a crown jewel in the making.
3 · Reply
InvestingIsFun45
InvestingIsFun45 Oct. 31 at 12:00 AM
$TGTX earnings slated for Nov 4. This is from Apple.
0 · Reply
BuyNowUnlimited
BuyNowUnlimited Oct. 30 at 11:36 PM
$TGTX i think they announce earnings date tomorrow
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 30 at 11:35 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $TGTX Current Share Price: $34.31 Contracts: $TGTX January 15, 2027 $35 Calls Scale in: $9.90- $12.10 Scale out: $15.40-$19.80 Can Easily Capture: 60% ROI Blended DTE: 442 Days | Join Elites here: https://liquidtheta.com
0 · Reply
investor757
investor757 Oct. 30 at 9:58 PM
$TGTX Today was my wife’s first Briumvi infusion. The first hour, they gave her a steroid, Benadryl and Tylenol. That next four hours was the actual infusion. I am happy to report that she did great. She had said that it was simple. Good to hear. That final next hour was just monitoring. She has had no side effects at all, and said the whole process was long, but a piece of cake. She was told that the side effects can happen up to the first 24 hours, but the nurse said that with all of the meds she’s been on in the past, they do not feel she may experience anything negative. She feels great right now, and I’m hoping that continues. Second dose is two weeks from today. I appreciate all of your positivity and kind word from my last post about the upcoming treatment. Though I strongly believe in this medication, you never know how someone will react. While I’m (we all are here) also here to make a lot of money off of this, to see the positive that it does for people is incredible.
ern1in
ern1in Oct. 30 at 9:14 PM
$TGTX Mike Weiss .... On a mission !
0 · Reply
ern1in
ern1in Oct. 30 at 9:09 PM
$TGTX 5:08 pm ..... BRIUMVI commercial !
0 · Reply
InvestingIsFun45
InvestingIsFun45 Oct. 30 at 8:43 PM
$TGTX TGTX Upcoming Earnings TG Therapeutics' Q3 2025 earnings is scheduled for Monday, November 3, 2025, with a conference call scheduled at 8:30 AM ET. Source: https://www.marketbeat.com/stocks/NASDAQ/TGTX/earnings/#:~:text=TGTX%20Upcoming%20Earnings,Estimated%20and%20Actual%20Earnings%20Data
1 · Reply
CedarPark
CedarPark Oct. 30 at 7:56 PM
$TGTX had to add a bit more right here at the end of the day, just a good feeling. BUY.
0 · Reply
tkstockpicker
tkstockpicker Oct. 30 at 7:39 PM
$TGTX Still holding…
0 · Reply
FE123
FE123 Oct. 30 at 7:18 PM
$IOVA $TGTX $TENX Lets Go!!
0 · Reply
ern1in
ern1in Oct. 30 at 5:54 PM
$TGTX 1:52 pm > Just saw a BRIUMVI commercial on Peacock .......
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 30 at 5:05 PM
The attached table compares $SNDX actual product sales by quarter post FDA approval/launch versus a handful of peers that exited via M&A & those still independent (both peer groups trade at meaningfully larger valuations). SNDX sub-totaled sales are all Revuforj + half of Niktimvo If the message is not painfully obvious, it is apparent that SNDX product sales are competitive with all of the subject peers yet SNDX trades at a fraction of their valuation. These are not projections nor analyst forecasts. These are valuations as multiples of actual sales. SNDX will report Revuforj Q3 2025 sales (its 4th quarter on the market) this coming Monday. All peers, especially $TGTX $ARQT $TARS have pipelines, just like SNDX, that may add valuation in the future making comparisons to actuals mis-leading. This is not investment advice. $XBI
2 · Reply
Auphiliate
Auphiliate Oct. 30 at 4:56 PM
0 · Reply
200_pips
200_pips Oct. 30 at 3:52 PM
$TGTX God knows why it's not above 40 at this stage knowing next year very good chance of hitting blockbuster 1B revenue.
1 · Reply
Lions1_83
Lions1_83 Oct. 30 at 2:21 PM
0 · Reply
Quad_
Quad_ Oct. 30 at 2:21 PM
$TGTX Something knows someone!
1 · Reply
BioAmerica
BioAmerica Oct. 30 at 2:04 PM
$TGTX Merck says they still looking for deals of up to $10B range and willing to go even larger.
2 · Reply
timfris
timfris Oct. 30 at 2:00 PM
$TGTX kind of overweight here, would be nice for a buyout.
0 · Reply